Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

Alterity Therapeutics ( (AU:ATH) ) has shared an announcement.

Alterity Therapeutics will showcase multiple aspects of its Multiple System Atrophy program at three medical meetings in May 2026, underscoring the momentum behind ATH434 and its broader clinical strategy. The company’s collaborators will present data on progressive iron accumulation in early MSA using quantitative susceptibility mapping, results from a randomized, placebo-controlled ATH434 study using CSF NfL as a covariate, and a clinical update with Phase 3 planning for ATH434.

These appearances in Cape Town, Sydney, and London position Alterity more prominently within the neurodegeneration field as it prepares a pivotal Phase 3 trial in a rare, rapidly progressive condition with significant unmet need. The emphasis on advanced imaging, robust clinical trial design, and Phase 3 readiness signals to clinicians and investors that Alterity is transitioning from proof-of-concept into potential late-stage development, which could influence future partnerships and funding opportunities if the program continues to advance successfully.

The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy and related Parkinsonian disorders. Its lead asset, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial for MSA, supported by positive data in an open-label Phase 2 study in advanced MSA, and the company operates from Melbourne and San Francisco with a broader discovery platform targeting neurological disease pathology.

Average Trading Volume: 9,722,629

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$108.8M

For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.